Abstract
Narrow activity spectrum and toxicological considerations are major shortcomings of the current therapeutics used for the treatment of sleeping sickness. During the last decennial rational drug design approaches have entered the field and have opened new horizons for the future treatment of Trypanosoma infections. This short review summarizes the present status of antitrypanosomal rational drug design with special focuss on gGAP[)H as worked out in the authors' laboratory.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
